Literature DB >> 20363518

Predicting 22q11.2 deletion syndrome: a novel method using the routine full blood count.

N Naqvi1, S J Davidson, D Wong, P Cullinan, M Roughton, V L Doughty, R C G Franklin, P E F Daubeney.   

Abstract

BACKGROUND: 22q11.2 deletion syndrome is common affecting nearly 1 in 3000, including many with DiGeorge Syndrome and 5% of individuals with congenital heart disease. Diagnosis is important because affected patients have impaired immune function and may suffer high mortality rates if given non-irradiated blood products from graft versus host disease. Symptomatic hypocalcaemia may also occur. Our objective was to determine whether mean platelet volume (MPV), available from the routine full blood count, may be a useful and rapid indicator of 22q11.2 deletion.
METHOD: A retrospective case control cohort study analysing MPV and 22q11.2 deletion status was performed in a paediatric population (n = 166) undergoing cardiac surgery between 1999 and 2005.
RESULTS: Twenty children were 22q11.2 positive. The median MPV was significantly larger for the 22q11.2 positive patient group compared to the non-22q11.2 patients (10.9fL versus 8.6fL, p<0.001). The area under the curve of the receiver operating characteristics (ROC) curve of MPV was large enough (0.85) to enable the accurate prediction of 22q11.2 deletion using MPV.
CONCLUSIONS: MPV is a useful screening test, involving no extra laboratory work, cost or patient discomfort. MPV>10fL is a positive predictor of the presence of 22q11.2 deletion in children with congenital heart disease (specificity 89.7%). This finding should aid rapid decision-making for ordering irradiated blood products to prevent potentially fatal transfusion-associated graft versus host disease. It will alert clinicians to monitor serum calcium levels closely to prevent hypocalcaemic seizures.
Copyright © 2010. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20363518     DOI: 10.1016/j.ijcard.2010.02.027

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

Review 1.  CHD associated with syndromic diagnoses: peri-operative risk factors and early outcomes.

Authors:  Benjamin J Landis; David S Cooper; Robert B Hinton
Journal:  Cardiol Young       Date:  2015-09-08       Impact factor: 1.093

2.  Hemizygosity for the gene encoding glycoprotein Ibβ is not responsible for macrothrombocytopenia and bleeding in patients with 22q11 deletion syndrome.

Authors:  N M J Zwifelhofer; R S Bercovitz; L A Weik; A Moroi; S LaRose; P J Newman; D K Newman
Journal:  J Thromb Haemost       Date:  2019-01-22       Impact factor: 5.824

3.  Hematological abnormalities and 22q11.2 deletion syndrome.

Authors:  Rafael Fabiano Machado Rosa; Rosana Cardoso Manique Rosa; Pedro Paulo Albino Dos Santos; Paulo Ricardo Gazzola Zen; Giorgio Adriano Paskulin
Journal:  Rev Bras Hematol Hemoter       Date:  2011

4.  Effect of 22q11.2 deletion on bleeding and transfusion utilization in children with congenital heart disease undergoing cardiac surgery.

Authors:  Michelle K Brenner; Shanelle Clarke; Donna K Mahnke; Pippa Simpson; Rachel S Bercovitz; Aoy Tomita-Mitchell; Michael E Mitchell; Debra K Newman
Journal:  Pediatr Res       Date:  2015-10-22       Impact factor: 3.756

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.